BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Bumble

Freshpet

OrganiGram Holdings Inc.

Tesla

Dish Network (NASDAQ:DISH), down 10% to $4.94, reported a drop in third-quarter revenue amid declining pay-TV subscribers,  triggering a loss for its fiscal third quarter. The US owner of the direct-broadcast satellite provider Dish said in a statement that pay-TV subscribers decreased by roughly 64,000 in Q3, compared to a net increase of approximately 30,000 in the year-ago quarter.

Tesla, Organigram, BioNTech, Dish, Bumble, FreshPet, Berkshire Hathaway – Stocks on the move

BioNTech unexpectedly reported a third-quarter profit and better-than-expected sales on Monday, pushing BNTX stock higher.

BioNTech Stock Jumps On Surprise Profit, Sales Beat

Shares have dropped 36% this year as demand for its coronavirus inoculations has fallen.

BioNTech Earnings Beat. Pfizer's Vaccine Partner Battles Covid Downturn.

BioNTech SE has lowered its forecast for this year's Covid-19 vaccine sales by 20%, becoming the latest drugmaker to adjust its expectations in the post-pandemic era. The German company said it now expects 2023 vaccine sales of around €4 billion, down from previous guidance of €5 billion.

BioNTech slashes revenue outlook amid lower Covid vaccine sales

BioNTech SE's stock BNTX, +3.56% rallied premarket after the company posted a surprise profit for the third quarter and revenue that beat estimates, even as it was hit by lower COVID-19 vaccine revenue. The German company said it had net profit of 160.6 million euros ($172.7 million), or 67 cents a share, down from EUR1.785 billion, or EUR6.98 a share, in the year-earlier period.

BioNTech's stock rallies after it posts surprise Q3 profit and revenue that tops estimates

BioNTech has cut its 2023 revenue target by about 1 billion euros ($1.1 billion) on lower demand for the COVID-19 vaccine made with Pfizer but said the impact from write-downs at its U.S. partner was less then initially thought.

BioNTech cuts 2023 revenue target on reduced prospects for vaccine

Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221 and mRNA cancer vaccine candidate BNT116 Progress across the oncology pipeline with multiple late-stage trials initiated since third quarter start New and expanded strategic collaborations reflect BioNTech's commitment to delivering transformational therapies for oncology and infectious diseases Successful launches of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine in markets worldwide Updated 2023 COVID-19 vaccine revenue guidance of around €4 billion Guidance reduction of planned 2023 R&D expenses to €1.8-2.0 billion and SG&A expenses to €600-650 million First nine months of 20231 revenues of €2.3 billion2, net profit of €472 million and diluted earnings per share of €1.94 ($2.113) Conference call and webcast scheduled for November 6, 2023, at 8:00 am ET (2:00 pm CET) MAINZ, Germany, November 6, 2023 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three and nine months ended September 30, 2023, and provided an update on its corporate progress. “Over the last quarter, we complemented our investigational pipeline with ADC candidates, initiated later-stage clinical trials and presented significant data across modalities including cancer vaccines, cell therapies, ADCs and immune checkpoint modulators.

BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioNTech SE - BNTX

NEW YORK , Oct. 26, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioNTech SE ("BioNTech" or "the Company") (NASDAQ: BNTX). Investors who purchased BioNTech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/bntx.

BioNTech SE (BNTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Adams Resources & Energy

Healthcare Services Group

inTEST

PBF Energy

Tower Semiconductor

Veracyte

Ahead of possible volatility in the market, investors may find some measure of confidence in undervalued stocks. From a psychological perspective, companies that sit well outside the well-beaten path offer the perception that they trade below their intrinsic value.

7 Undervalued Stocks That Analysts Love Right Now

Pfizer

Pfizer and BioNTech said an early trial of a combined Covid-19 and influenza vaccine had produced positive data. The companies are set for a race with Moderna to release the first combination vaccine.

Pfizer Progresses Combo Covid Vaccine. It's Competing with Moderna.

Pfizer Inc. PFE and German partner BioNTEch SE BNTX announced positive results from a Phase 1/2 trial of their combined mRNA flu/COVID vaccine on Thursday in adults aged 18 to 64. The vaccine candidates were compared to a licensed influenza vaccine and the companies' omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.

Pfizer and BioNTech announce positive data in early trial of flu/COVID combination vaccine

Pfizer and German partner BioNTech said on Thursday that their vaccine to prevent flu and COVID-19 generated a strong immune response against the virus strains in early- to mid-stage trials.

Pfizer, BioNtech say flu-COVID shot generates immune response

NEW YORK and MAINZ, GERMANY, October 26, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study ( NCT05596734 ) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit. The data from the trial showed that the companies' lead formulations demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.

Pfizer and BioNTech - Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies' Omicron BA.4/BA.5-adapted bivalent COVID.

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

BioNTech's coronavirus portfolio isn't doing as well as last year. The company has a rich pipeline, but few of its products are in late-stage studies.

Is BioNTech Stock a Buy Now?

MAINZ, Germany, October 23, 2023 (GLOBE NEWSWIRE) –  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced follow-up data from its ongoing first-in-human Phase 1/2 trial (NCT04503278; 2019-004323-20) evaluating the safety and efficacy of the Company's Claudin-6 (CLDN6)-directed CAR-T cell therapy candidate BNT211 in patients with CLDN6-positive refractory/relapsed solid tumors. The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac. At the ESMO Congress 2023 in Madrid, Prof. John Haanen, M.D., Ph.D., Netherlands Cancer Institute (NKI), Amsterdam, Netherlands presented the data in an oral late-breaking data session which confirms the positive interim data presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA.

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

MAINZ, Germany , October 23, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2023 on Monday, November 6th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2023.

BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023

Moderna

Novavax

Novavax NVAX, -5.56% stands out as a stark reminder of the biotech sector's faltering steps in 2023. Once renowned for its Nuvaxovid COVID-19 vaccine, the Maryland-based company is now grappling with financial issues, reflecting the broader challenges that continue to plague the pharmaceutical sector this year.

Biotech stocks are in a post-pandemic slump and recovery in 2024 is questionable

AMC Entertainment

Charter Communications

Coinbase

Office Depot

Cassava Sciences Inc

Warner Bros Discovery Inc

One of the big slogans favored by CNBC pundit Jim Cramer is, “There's always a bull market somewhere.” I believe that's true.

7 Stocks That Are Heading for a Train Wreck

MAINZ, Germany, October 19, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that the first patient has been treated in a Phase 2 clinical trial evaluating the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (also known as BNT122, RO7198457) in resected pancreatic ductal adenocarcinoma (PDAC). PDACs are solid tumors with a poor prognosis reflected in a 5-year overall survival rate of only 8-10%1 ,2, high recurrence rates3 and limited treatment options.

BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Moderna stock and BioNTech stock led a sell-off Monday among Covid vaccine makers after Pfizer slashed its full-year guidance.

Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion

Pfizer slashed its revenue forecasts on Friday amid falling demand for its Covid vaccine and antiviral drug Paxlovid.

Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

Shares of BioNTech SE BNTX, -4.89% sank 6.1% toward a 2 1/2-year low in premarket trading Monday, after the Germany-based biotechnology company disclosed that it currently expects to record a charge of up to EUR900 million ($947 million) in the third quarter as it writes of inventory of COVID-19 vaccine Comirnaty. The disclosure comes in response to Pfizer Inc.'s PFE, -2.46% announcement Friday that it was cutting 2023 revenue expectations by $9 billion due to its COVID products, which were developed with BioNTech.

BioNTech's stock sinks after disclosing expected charge of up to nearly $1 billion resulting from Pfizer's write offs of COVID products

Covid vaccine developer BioNTech is to take a write-down of up to €900 million on its stocks of jabs following a similar provision by partner Pfizer last week. Pfizer had said that the write-offs relate to raw materials purchased during the pandemic, as well as Covid-19 vaccine doses adapted to non-XBB.1.5 variants.

News for BioNTech SE Stock (BNTX)